Nuvectis Pharma Inc (NVCT)

Mar 14, 2025, 8:00 AM EDT - 4 weeks ago

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

Feb 7, 2025, 8:30 AM EST - 2 months ago

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option

Feb 6, 2025, 2:00 PM EST - 2 months ago

Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A Comeback

Feb 5, 2025, 9:01 AM EST - 2 months ago

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

Feb 4, 2025, 4:05 PM EST - 2 months ago

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

Nov 14, 2024, 2:23 PM EST - 5 months ago

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug

Nov 5, 2024, 7:00 AM EST - 5 months ago

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

Oct 28, 2024, 8:21 AM EDT - 5 months ago

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

DRUG

Aug 29, 2024, 8:00 AM EDT - 8 months ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Aug 6, 2024, 8:28 AM EDT - 8 months ago

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights

May 16, 2024, 8:30 AM EDT - 11 months ago

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

Apr 8, 2024, 8:30 AM EDT - 1 year ago

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

Mar 19, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma to Present at the 36th Annual Roth Conference

Mar 14, 2024, 9:00 AM EDT - 1 year ago

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Mar 5, 2024, 8:00 AM EST - 1 year ago

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights

Feb 9, 2024, 8:32 AM EST - 1 year ago

Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Feb 9, 2024, 8:00 AM EST - 1 year ago

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Jan 3, 2024, 8:00 AM EST - 1 year ago

Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 8, 2023, 8:00 AM EST - 1 year ago

Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

Sep 25, 2023, 7:30 PM EDT - 1 year ago

Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation

Sep 21, 2023, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

Sep 6, 2023, 8:03 AM EDT - 1 year ago

Nuvectis: Early Stage Company That's Low On Cash

Sep 6, 2023, 8:00 AM EDT - 1 year ago

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

Aug 17, 2023, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma

Aug 9, 2023, 8:00 AM EDT - 1 year ago

Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights

May 15, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

May 10, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights

Apr 27, 2023, 10:14 AM EDT - 2 years ago

Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

Apr 10, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma

Mar 17, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting

Mar 10, 2023, 8:00 AM EST - 2 years ago

Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

Mar 7, 2023, 8:00 AM EST - 2 years ago

Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights

Dec 1, 2022, 8:00 AM EST - 2 years ago

FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma

Nov 8, 2022, 8:00 AM EST - 2 years ago

Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights

Oct 18, 2022, 8:00 AM EDT - 2 years ago

Nuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 3, 2022, 4:30 PM EDT - 2 years ago

Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference

Sep 28, 2022, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Formation of a Scientific Advisory Board

Sep 13, 2022, 8:30 AM EDT - 2 years ago

Nuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model of ARID1a-Mutated Gastric Carcinoma

Sep 7, 2022, 8:30 AM EDT - 2 years ago

Nuvectis Pharma, Inc. to Present at Upcoming Investment Conferences

Aug 5, 2022, 8:00 AM EDT - 2 years ago

Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights

Aug 1, 2022, 8:30 AM EDT - 2 years ago

Nuvectis Pharma Announces Closing of Approximately $15.9 Million Private Placement

Jun 21, 2022, 8:15 AM EDT - 3 years ago

Nuvectis Pharma Announces FDA Clearance of IND for NXP800

Jun 13, 2022, 8:30 AM EDT - 3 years ago

Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients

May 20, 2022, 10:21 AM EDT - 3 years ago

Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference

May 10, 2022, 8:30 AM EDT - 3 years ago

Nuvectis Pharma, Inc. Reports First Quarter 2022 Financial Results and Business Highlights

Apr 13, 2022, 8:30 AM EDT - 3 years ago

Nuvectis Pharma Recaps Poster Presentation Highlights for NXP900 at the 2022 American Association for Cancer Research (AACR) Conference